<DOC>
	<DOCNO>NCT00674141</DOCNO>
	<brief_summary>The study aim assess safety efficacy nasale administration Dexamethasone relapse MS patient</brief_summary>
	<brief_title>Nasal Administration Dexamethasone Multiple Sclerosis ( MS ) Treatment</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>MS patient esatblished relapse remit attack increase EDSS least 1 point least one day child 18 pregnant patient patient diabetes know allergy steroid patient receive steroid within 3 month prior study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Multiple Sclerosis , relapse remitting , Dexamethasone</keyword>
</DOC>